Table 1 |
||||||||
|
Recurrent thrombosis in the patients with antiphospholipid antibodies |
||||||||
| Study design |
N |
Mean age Years |
Entry criteria |
Patient Characteristics |
Mean Follow up Years |
Patients with recurrent events No. (%) |
Number of recurrent events All (arterial/venous) |
Reference |
|
|
||||||||
| Retrospective |
70 48W 22M |
45.5 ± 17.3 |
aPL (aCL/LA) + arterial/venous thrombosis (1st event) |
PAPS 51 SLE 14 ITP 5 |
5.2 |
37/70 (53%) |
54 |
Rosove MH et al. Ann Intern Med 1992 |
|
|
||||||||
| Retrospective |
19 16W 3M |
26 (15–40) |
aPL (aCL/LA) + venous thrombosis (1st event) |
PAPS 1 SLE 12 Lupus like 6 |
8 |
12/19 (63%) |
37 (3/34) |
Derksen R et al. Ann Rheum Dis 1993 |
|
|
||||||||
| Retrospective |
147 124W 23M |
32 (14–66) |
aPL (aCL/LA) + arterial/venous thrombosis (1st event) |
PAPS 62 SLE 66 Lupus like 19 |
7 |
101/147 (69%) |
186 (75/111) |
Khamashta M et al. N Eng J Med 1995 |
|
|
||||||||
| Prospective |
360 242W 118M |
39 (2–78) |
aPL (aCL/LA) (117 aPL pt with previous arterial/venous thrombosis) |
SLE 69 Lupus like 66 |
4 |
25/117 (21.3%) |
25 |
Finazzi G et al. Am J Med 1996 |
|
|
||||||||
| Prospective |
412 181W 231M |
60.2 |
Venous thrombosis (1st event) allocated 6 months warfarin |
- |
4 |
20/68 aCL+ (29%) 47/344 aCL- (14%) |
67 (-/67) |
Schulman S et al. Am J Med 1998 |
|
|
||||||||
| Prospective |
56 48W 8M |
37 ± 10 |
APS (aPL + thrombosis and/or fetal loss) (43 patients with previous arterial/venous thrombosis) |
PAPS only |
5 |
14/43 (32.5) |
16 (10/6) |
Turiel M et al. Stroke 2005 |
|
W – women; M – men; aPL – antiphospholipid antibodies; aCL – anticardiolipin antibodies; LA – lupus anticoagulant; PAPS – primary antiphospholipid syndrome; SLE – systemic lupus erytematosus; Lupus like – Lupus like disease; ITP – chronic idiopathic thrombocytopenic purpura. | ||||||||
Fonseca and D'Cruz Journal of Autoimmune Diseases 2008 5:6 doi:10.1186/1740-2557-5-6 |
||||||||
